Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19

Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore,...

Descripción completa

Detalles Bibliográficos
Autor principal: Buschard, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372998/
https://www.ncbi.nlm.nih.gov/pubmed/32759008
http://dx.doi.org/10.1016/j.mehy.2020.110127
_version_ 1783561421171195904
author Buschard, Karsten
author_facet Buschard, Karsten
author_sort Buschard, Karsten
collection PubMed
description Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended.
format Online
Article
Text
id pubmed-7372998
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-73729982020-07-22 Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19 Buschard, Karsten Med Hypotheses Article Fenofibrate, which is a PPAR-alfpha agonist, increases the level of sulfatide. In this letter we hypothesize on the background of various findings that this is beneficial against COVID-19. Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects. Therefore, a trial giving fenofibrate to patients with corona virus infection is recommended. Elsevier Ltd. 2020-10 2020-07-21 /pmc/articles/PMC7372998/ /pubmed/32759008 http://dx.doi.org/10.1016/j.mehy.2020.110127 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Buschard, Karsten
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
title Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
title_full Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
title_fullStr Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
title_full_unstemmed Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
title_short Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19
title_sort fenofibrate increases the amount of sulfatide which seems beneficial against covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372998/
https://www.ncbi.nlm.nih.gov/pubmed/32759008
http://dx.doi.org/10.1016/j.mehy.2020.110127
work_keys_str_mv AT buschardkarsten fenofibrateincreasestheamountofsulfatidewhichseemsbeneficialagainstcovid19

Ejemplares similares